Open Journal Systems

Smoking cessation in cardiovascular health

Dres Enrique Soto, Ana Lorenzo, Elba Esteves

Article ID: 1895
Vol 1, Issue 1, 2020

DOI: https://doi.org/10.54517/ccr.v1i1.1895
VIEWS - 49 (Abstract)

Abstract

The World Health Organization has identified noncommunicable diseases (NCDs) as one of the greatest challenges of this century, accounting for 71% of deaths worldwide. Smoking is considered one of the main modifiable risk factors affecting NCDs. There is ample evidence linking smoking to cardiovascular disease, particularly ischemic heart disease. The 2016 European Society of Cardiology Cardiovascular Prevention Guidelines establish smoking cessation as a class I, level of evidence A recommendation. The effect of nicotine generates a strong addiction that triggers a withdrawal syndrome when attempting to quit smoking. Therefore, it is necessary to be familiar with the strategies for the treatment of tobacco addiction, which include: minimal intervention, cognitive-behavioral resources and pharmacological treatment such as nicotine replacement therapy, bupropion and varenicline. At present, there is insufficient scientific evidence to recommend electronic devices.

Keywords

tobaccoism; tobacco use cessation; health cardiovascular health

Full Text:

PDF

References

1. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: WHO, 2014 [cited 2018 Aug 31]. Available from: http://www.who.int/nmh/publications/ncd-sta-tus-report-2014/en/.

2. World Health Organization. Noncommunicable diseases: 1 June 2018. [Web page]. Geneva: WHO, 2018 [cited 2018 Aug 31]. Available from: http://www.who.int/ en/news-room/fact-sheets/detail/noncommunica- ble-diseases.

3. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1659-724.

4. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, et al. Priority actions for the non-communicable disease crisis. Lancet 2011;377 (9775):1438–47.

5. Zabert G, Jiménez Ruiz C, Zabert I. What should cardiologists know about pharmacological treatment for smoking cessation? Rev Urug Cardiol 2011; 26(3):251–62.

6. World Health Organization. Guidelines on protection from exposure to tobacco smoke: purpose, objectives and main considerations. Geneva: WHO, 2007 [cited 2018 Aug 31]. Available from: www.who.int/fctc/cop/art%208%20guidelines_spa- nish.pdf. [Accessed: 31 August 2018].

7. Ambrose J, Barua R. The pathophysiology of ciga- rette smoking and cardiovascular disease: an update.J Am Coll Cardiol 2004; 43(10):1731–7.

8. Sandoya E, Sebrié E, Bianco E, Araújo O, Correa A, Davyt O, et al. Impact of indoor smoking bans on admissions for acute myocardial infarction in Uruguay. Rev Méd Urug 2010; 26(4): 206–15.

9. Raupach T, Schäfer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J 2006; 27(4): 386–92.

10. Teo K, Ounpuu S, Hawken S, Pandey M, Valentin V, Hunt D, et al. Tobacco use and risk of myocar- dial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368(9536): 647–58.

11. Doll R, Peto R, Boreham J, Sutherland I. Morta- lity in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328(7455): 1519.

12. Barnoya J, Glantz S. Cardiovascular effects of se- cond hand smoke: nearly as large as smoking. Circu- lation 2005; 111(20): 2684–98.

13. Sebrié E, Sandoya E, Hyland A, Bianco E, Glantz S, Cummings K. Hospital admissions for acute myo cardial infarction before and after implementation of a comprehensive smoke-free policy in Uruguay. Tob Control 2013;22(e1):e16–20.

14. National Resources Fund. World tobacco-free day: communication made on May 31, 2018.Montevideo: FNR, 2018 [cited 2018 Aug 31]. Available from: http://www. fnr.gub.uy/n_dia_tabaquismo_2018

15. Prescott E, Hippe M, Schnohr P, Hein H, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316(7137):1043–7.

16. Spanish Society of Cardiology. ESC 2016 guideline on prevention of cardiovascular disease in clinical practice. Rev Esp Cardiol 2016;69(10): 939.e1–e87.

17. Lorenzo García A, Baraibar Penco R, Melgar Álvarez S, Parodi Debat C, Gambogi Irigaray R, Cenández Martínez A, et al. Guía Nacional para el Abordaje del Tabaquismo: Uruguay 2009.Montevideo: MSP, 2009.

18. Chow C, Jolly S, Rao-Melacini P, Fox K, Anand S, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121(6):750–8.

19. Di Chiara G. Role of dopamine in the behavioral actions of nicotine related to addiction. Eur J Pharmacol 2000; 393(1–3):295–314.

20. Hughes J. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007;9(3):315–27.

21. McRobbie H, Thornley S. The importance of treating tobacco dependence. Rev Esp Cardiol 2008;61(6):620–8.

22. Shiffman S, Brockwell S, Pillitteri J, Gitchell J. Use of smoking-cessation treatments in the Uni- ted States. Am J Prev Med 2008;34(2):102–11.

23. Hughes J, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99(1):29-38.

24. Uruguay. Ministry of Health. Global adult smoking survey: Global Adult Tobacco Sur- vey (GATS) Uruguay 2017. [In press]. Available at: http://www.msp.gub.uy/sites/default/files/archi- vos_adjuntos/PRESENTACI%C3%93N% 20GATS_Mayo%202017%20%28edit%29.ppt. [Con- sult: 31 August 2018].

25. Lader D. Smoking-related behaviour and attitudes, 2006: a report on research using the National Statis- tics Omnibus Survey produced on behalf of the Infor- mation Centre for health and social care. Newport, UK: Office for National Statistics, 2007.

26. United States. Department of Health and Human Services. Treating tobacco use and dependence. Rockville, MD: Department of Health and Human Services, 2000.

27. Stead L, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;(5):CD000165. doi: 10.1002/14651858.CD000165. pub4.

28. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation.Cochrane Database Syst Rev2007;(1):CD000031.

29. Rollema H, Hajós M, Seymour P, Kozak R, Majchrzak M, Guanowsky V, et al. Preclinical pharmacology of the alpha4 beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009;78(7): 813-24.

30. Jiménez Ruiz C, Jaén C. Tobacco dependence treatment guide. [Treating tobacco use and dependence: 2008 update. Clinical practice guideline of U.S. Department of Health and Human Services. Public Health Service May 2008]. Madrid: SEPAR, 2010.

31. World Health Organization. Electronic nicotine delivery systems and nicotine-free systems (SEAN/SSSN), WHO report, Seventh Meeting of the Conference of the Parties to the WHO Framework Convention on Tobacco Control, Delhi, (7-12 November 2016), FCTC/COP/7/11. Available from: http://www.who.int/fctc/cop/cop/cop7/FCTC_COP_7_11_EN.pdf..

32. Doval H, Tajer C. Evidencias en Cardiología. 8 ed.Buenos Aires: GEDIC, 2016.

33. Bhatnagar A, Whitsel L, Ribisl K, Bullen C, Chaloupka F, Piano MR, et al. Electronic Ciga- rrettes: a policy statement from the American Heart Association. Circulation 2014; 13016):1418–36.